Edition:
India

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

32.10EUR
22 Jun 2018
Change (% chg)

€-0.75 (-2.28%)
Prev Close
€32.85
Open
€33.15
Day's High
€33.15
Day's Low
€31.85
Volume
90,773
Avg. Vol
136,859
52-wk High
€39.35
52-wk Low
€8.43

Latest Key Developments (Source: Significant Developments)

Mithra Pharmaceuticals And Orifarm Sign LSA For Vaginal Contraception Ring In Denmark
Thursday, 21 Jun 2018 

June 21 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA AND ORIFARM SIGN LSA FOR VAGINAL CONTRACEPTION RING IN DENMARK.VAGINAL RING SHALL BE MANUFACTURED AT MITHRA CDMO.AGREEMENT FOLLOWS MYRINGTM LICENSES1 CLOSED WITH MAYNE PHARMA, GYNIAL, ADAMED AND ALVOGEN FOR THE US, AUSTRIA, THE CZECH REPUBLIC AND RUSSIA, RESPECTIVELY.ORIFARM WILL HAVE RIGHTS TO SELL RING IN DENMARK MARKET WORTH APPROXIMATELY EUR 0.75 MILLION.IN ADDITION TO DOWNPAYMENT AND MILESTONE PAYMENTS, SEES ANNUAL REVENUES AFTER COMMERCIAL LAUNCH.  Full Article

Mithra Successfully Raises 77.5 Million Euros
Thursday, 31 May 2018 

May 31 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA SUCCESSFULLY RAISES EUR 77.5 MILLION.PRIVATE PLACEMENT OF 2,672,414 NEW SHARES THROUGH AN ACCELERATED BOOKBUILD OFFERING.PRICE OF EUR 29.00 PER SHARE, WHICH REPRESENTS A 10.2% DISCOUNT TO YESTERDAY'S CLOSING PRICE.TOTAL NUMBER OF ISSUED AND OUTSTANDING SHARES POST-TRANSACTION AT 37,639,495.  Full Article

Mithra Pharmaceuticals Launches Capital Increase
Wednesday, 30 May 2018 

May 30 (Reuters) - MITHRA PHARMACEUTICALS SA ::LAUNCHES CAPITAL INCREASE BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING.CAPITAL INCREASE OF APPROXIMATELY EUR 60 MILLION.POSSIBILITY TO INCREASE THE SIZE OF THE PRIVATE PLACEMENT TO UP TO 3,880,440 NEW SHARES IN TOTAL.ACCELERATED BOOKBUILD OFFERING WILL COMMENCE IMMEDIATELY.TRADING IN MITHRA SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD.TRADING IN SHARES IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF PRIVATE PLACEMENT.KBC SECURITIES AND KEMPEN ARE ACTING AS JOINT BOOKRUNNERS.BELFIUS BANK ACTS AS LEAD MANAGER IN COOPERATION WITH KEPLER CHEUVREUX IN THE PRIVATE PLACEMENT.  Full Article

Mithra Pharmaceuticals Announces Injectable Contract With Midas Pharma
Wednesday, 16 May 2018 

May 16 (Reuters) - MITHRA PHARMACEUTICALS SA ::ANNOUNCES INJECTABLE CONTRACT WITH MIDAS PHARMA.FINANCIAL TERMS OF CONTRACT WERE NOT DISCLOSED.CONTRACT FOR DEVELOPMENT AND POTENTIAL MANUFACTURING OF STERILE INJECTABLE.  Full Article

Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study
Thursday, 19 Apr 2018 

April 19 (Reuters) - MITHRA PHARMACEUTICALS SA ::ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE.STUDY CONCLUDED THAT 15 MG OF E4 WAS OPTIMAL ORAL MINIMUM DOSE FOR EFFECTIVE TREATMENT OF VMS..THIS DOSE COHORT DEMONSTRATES REDUCTION OF OVER 80% IN FREQUENCY OF MODERATE TO SEVERE VMS WHEN COMPARED TO BASELINE..  Full Article

Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma
Thursday, 12 Apr 2018 

April 12 (Reuters) - MITHRA PHARMACEUTICALS SA ::SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA.TOP LINE RESULTS FOR ESTELLE PHASE 3 TRIALS EXPECTED IN Q3 2018 AND Q1 2019.ELIGIBLE TO RECEIVE UP TO EUR 15 MILLION IN UPFRONT PAYMENTS AND SALES-RELATED REVENUES.TO MANUFACTURE ESTELLE FOR SEARCHLIGHT AND RECEIVE GUARANTEED ANNUAL RECURRING REVENUES.THE ANNUAL RECURRING REVENUES TO BE BASED ON MINIMUM ANNUAL QUANTITIES.AGREEMENT COULD ACHIEVE REVENUES OF AT LEAST EUR 50 MILLION FOR MITHRA.  Full Article

Mithra And Alvogen Sign LSA For Vaginal Contraception Ring In Russia
Friday, 16 Mar 2018 

March 16 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA AND ALVOGEN SIGN LSA FOR VAGINAL CONTRACEPTION RING IN RUSSIA.GRANTS EXCLUSIVE LICENSE FOR VAGINAL CONTRACEPTION RING TO ALVOGEN FOR COMMERCIALIZATION IN RUSSIA.VAGINAL RING SHALL BE MANUFACTURED AT MITHRA CDMO.ALVOGEN WILL HAVE THE RIGHTS TO SELL THE RING IN RUSSIA‍​.  Full Article

Mithra Pharmaceuticals And Adamed Sign Commercialization Agreement For Myring™ In The Czech Republic
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - MITHRA PHARMACEUTICALS SA ::MITHRA AND ADAMED SIGN COMMERCIALIZATION AGREEMENT FOR MYRING™ IN THE CZECH REPUBLIC.GRANTS NON-EXCLUSIVE 10-YEAR LICENSE FOR VAGINAL CONTRACEPTION RING MYRING TM TO ADAMED FOR COMMERCIALIZATION IN CZECH REPUBLIC.AGREEMENT FOLLOWS US AND AUSTRIAN LICENSE GRANTED TO MAYNE PHARMA AND GYNIAL, RESPECTIVELY.MYRING TM TO BE MANUFACTURED AT MITHRA CDMO.FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Mithra Pharmaceuticals Announces Injectables Agreement With GSP
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Mithra Pharmaceuticals Sa ::ANNOUNCES INJECTABLES AGREEMENT WITH GSP.MITHRA CLOSES CONTRACTS WITH LEADING GENERICS PLAYER GSP FOR DEVELOPMENT AND SUPPLY OF 4 HORMONAL INJECTABLES.CONTRACTS SHOULD ALLOW FOR EUROPEAN AND US GMP APPROVAL OF INJECTABLE SECTION AT MITHRA CDMO.EUR 2.4 MILLION DOWNPAYMENT.AGREEMENT SHOULD GENERATE SEVERAL MILLION EUROS IN ANNUAL REVENUE OVER COURSE OF 10-YEAR CONTRACTS.AGREEMENT COMPRISES DEVELOPMENT AND PRODUCTION OF FOUR PRODUCTS.WELL-POSITIONED TO RECEIVE GOOD MANUFACTURING PRACTICE (GMP) APPROVAL FROM EUROPEAN AND AMERICAN AUTHORITIES FOR ITS INJECTABLES SECTION‍​.  Full Article

Mithra Pharmaceuticals Finalizes Estelle Contract With Libbs
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Mithra Pharmaceuticals Sa ::FINALIZES ESTELLE CONTRACT WITH BRAZILIAN WOMEN’S HEALTH LEADER LIBBS.ESTELLE IS CURRENTLY IN PHASE III TRIALS IN US AND CANADA AND EUROPE AND RUSSIA.ESTELLE TOP LINE RESULTS FOR US AND CANADA EXPECTED IN Q3 2018.ESTELLE TOP LINE RESULTS FOR EUROPE AND RUSSIA EXPECTED IN Q1 2019.  Full Article

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY